Assembly Biosciences Inc Company News
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with recurrent genital herpes by end of 2024 and interim Phase 1b data available in 1H2025Gilead Sciences, Inc. partnership supports advancement and strengthening of antiviral pipeline targeting serious viral diseases S
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024. The company anticipates that its common s
Looking at Assembly Biosciences, Inc.'s ( NASDAQ:ASMB ) insider transactions over the last year, we can see that...
Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D virusesInitial clinical data anticipated by end of year from first-in-human study of long-acting helicase-primase inhibitor targeting recurrent genital herpes (ABI-5366) and Phase 1b study of next-generation core inhibitor for chronic hepatitis B virus (ABI-4334)Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead)
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023. The Company granted Dr. Gaggar non-qualified stock options to purchase 500,000 shares of the Company’s common stock with an exercise price of $0.85 per share, the closing pri
--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Li
Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyondNow anticipate four development candidates from expanded pipeline in clinical development by the end of 2024Named Anuj Gaggar, MD, PhD, as chief medical officer $100 million upfront payment and investment received from Gilead in October extends projected cash runway into 2H 2025 SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: A
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar i
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., October 17, 2023--Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that preclinical and clinical data from its virology portfolio will be featured in two presentations at the upcoming Americ
Old Arcived News About Assembly Biosciences Inc
- Assembly Biosciences Appoints Biotech Veteran Alan J. Lewis to Board of Directors. [at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced ...
- Assembly Biosciences Expands Senior Leadership Team.
- Assembly Biosciences Inc.
- Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technolog.
- Assembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting. [at noodls] - - Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies- - Assembly Also Reporting New ...
- Assembly Biosciences to Present at Jefferies Microbiome Summit. [at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, announced that the ...
- Assembly Biosciences to Webcast Upcoming Investor Conferences.
- Assembly Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : September 21, 2015.
- ASSEMBLY BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report.
- ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F.
- ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a.
- ASSEMBLY BIOSCIENCES, INC. Financials.
- Clinical Study Shows Assembly Biosciences' Oral Gemicelâ„¢ Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications. [at noodls] - Clinical Study Shows Assembly Biosciences' Oral Gemicelâ„¢ Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications
- Clinical Study Shows Assembly Biosciences' Oral Gemicelâ„¢ Technology Can Achieve Targeted Delivery to the Lower GI Tract for M.
- ETF’s with exposure to Assembly Biosciences, Inc. : September 21, 2015.
- Ventrus Biosciences Files and Commences Mailing of Definitive Proxy Materials for July 10th Annual Meeting. [at noodls] - NEW YORK, June 9, 2014 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) ('Ventrus' or the 'Company') today announced that it has filed definitive proxy materials with the Securities and Exchange ...
Assembly Biosciences Inc Short Company Overview:
Assembly Biosciences Inc. is a biopharmaceutical company. The Company is focused in the field of infectious diseases such as the Hepatitis B virus (HBV) and clostridium difficile (CDAD). Assembly is developing two proprietary platforms: an HBV-cure platform focused on oral drugs with novel direct-acting mechanisms, and an orally-delivered microbiome therapeutics platform for treating CDAD.
